MMSL 2013, 82(4):180-184 | DOI: 10.31482/mmsl.2013.028

POTENTIAL ANTICLASTOGENIC EFFECT OF HYPERFORINReview article

Petronela Imreová1*, Eva Miadoková1, Eli¹ka Gálová1, Stephka Chankova2, Ivan Chalupa3
1 Department of Genetics, Faculty of Sciences, Comenius University, Bratislava, Slovak Republic
2 Institute of Biodiversity and Ecosystem Researches, Bulgarian Acad. Sci., Sofia, Bulgaria
3 Institute of Experimental Oncology, Slovak Academy of Sciences, Bratislava, Slovak Republic

Hyperforin is a prenylated phloroglucinol derivative which occurs in the plant Hypericum perforatum L. It has several medicinally important properties (antidepressant, anti-inflammatory, proapoptotic, antibacterial and antiangiogenic). To enable its medicinal use, it is necessary to investigate its potential genotoxic effect on human cell lines. We also observed an anticlastogenic effect of hyperforin towards the indirect mutagen benzo(a)pyrene. Benzo(a)pyrene is a widespread polycyclic aromatic hydrocarbon. We performed experiments on human tumor cell line HepG2, using the in vitro mammalian chromosome aberration test. We investigated two cytogenic parameters: the number of aberrant metaphases and the total number of chromosome aberrations. We found out that hyperforin was not genotoxic on human cell line HepG2. The second part of our results implies that hyperforin had an anticlastogenic effect against the indirect mutagen benzo(a)pyrene in our experimental conditions. In future we will continue our research by using another range of hyperforin concentrations, other cell lines and other chemical mutagens.

Keywords: hyperforin; benzo(a)pyrene; genotoxic; anticlastogenic; chromosomal aberrations

Received: April 29, 2013; Revised: August 21, 2013; Published: December 5, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Imreová, P., Miadoková, E., Gálová, E., Chankova, S., & Chalupa, I. (2013). POTENTIAL ANTICLASTOGENIC EFFECT OF HYPERFORIN. MMSL, 82(4), 180-184. doi: 10.31482/mmsl.2013.028
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Medina, M. A.; Martínez-Poveda, B.; Amores-Sánchez, M.I.; Quesada, A. R. Hyperforin: more than an antidepressant bioactive compound? Life Sci. 2006,79, 105-111. Go to original source... Go to PubMed...
    2. Bilia, A. R.; Gallori, S.; Vincieri, F. F. St. John's wort and depression: efficacy, safety and tolerability-an update. Life Sci. 2002, 70, 3077-3096. Go to original source... Go to PubMed...
    3. Laakmann, G.; Schüle, C.; Baghai, T.; Kieser, M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 1998, 31, 54-59. Go to original source... Go to PubMed...
    4. Di Carlo, G.; Borrelli, F.; Ernst, E.; Izzo, A. A. St John's wort: prozac from the plant kingdom. Trends Pharmacological Sci. 2001, 22, 292-297. Go to original source... Go to PubMed...
    5. Schempp, C. M.; Pelz, K.; Wittmer, A.; Schöpf, E.; Simon, J. C. Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria. Lancet. 1999, 353, 2129. Go to original source... Go to PubMed...
    6. Schempp, C. M.; Kirkin, V.; Simon-Haarhaus, B.; Kersten, A.; Kiss, J.; Termeer, C. C.; Gilb, B.; Kaufmann, T.; Borner, C.; Sleeman, J. P.; Simon, J.C. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene. 2002, 21, 1242-1250. Go to original source... Go to PubMed...
    7. Tedeschi, E.; Menegazzi, M.; Margotto, D.; Suzuki, H.; Förstermann, U.; Kleinert, H. Antiinflammatory actions of St. John's wort: inhibition of human inducible nitric-oxide synthase expression by down-regulating signal transducer and activator of transcription-1alpha (STAT-1alpha) activation. J. Pharmacol. Exp Ther. 2003, 307, 254-261. Go to original source... Go to PubMed...
    8. Dona, M.; Dell'Aica, I.; Pezzato, E.; Sartor, L.; Calabrese, F.; Della Barbera, M.; Donella-Deana, A.; Appendino, G.; Borsarini, A.; Caniato, R.; Garbisa, S. Hyperforin inhibits cancer invasion and metastasis. Cancer Res. 2004, 64, 6225-6232. Go to original source... Go to PubMed...
    9. Martínez-Poveda, B.; Quesada, A.R.; Medina, M.A. Hyperforin, a bioactive compound of St. John's wort, is a new inhibitor of angiogenesis targeting several key steps of the process. Int. J. Cancer. 2005, 117, 775-780. Go to original source... Go to PubMed...
    10. Fang, C.; Zhang, Q. Y. The role of small-intestinal P450 enzymes in protection againstsystemic exposure of orally administered benzo(a)pyrene. J. Pharmacol. Exp. Ther. 2010, 334, 156-163. Go to original source... Go to PubMed...
    11. Nebert, D. W. The Ah locus: Genetic differences in toxicity, cancer, mutation and birth defects. Crit Rev Toxicol. 1989, 20, 153-174. Go to original source... Go to PubMed...
    12. Ellard, S.; Mohammed, Y.; Dogra, S.; Wolfel, C.; Doehmer, J.; Parry, J. M. Use of genetically engineered V79 Chinese hamster cultures expressing rat liver CYP1A1, 1A2 and 2B1 cDNAs in micronucleus assays. Mutagenesis. 1991, 6, 461-470. Go to original source... Go to PubMed...
    13. Conney, A. H.; Chang, R. L.; Jerina, D. M.; Wei, S. J. Studies on the metabolism of benzo(a)pyrene and dose-dependent differences in the mutagenic profile of its ultimate carcinogenic metabolite. Drug Metab Rev. 1994, 26, 125-163. Go to original source... Go to PubMed...
    14. Miller, K. P.; Ramos, K. S.. Impact of cellular metabolism on the biological effects of benzo[a]pyrene and related hydrocarbons. Drug Metab Rev. 2001, 33, 1-35. Go to original source... Go to PubMed...
    15. Phillips, D. H. Polycyclic aromatic hydrocarbons in the diet. Mutat. Res. 1999, 443, 139-147. Go to original source... Go to PubMed...
    16. Elie, M. R.; Clausen, C. A.; Geiger, C. L. Reduction of benzo(a)pyrene with acid-activated magnesium metal in ethanol: a possible application for environmental remediation. J Hazard Mater. 2011, 203-204, 77-85. Go to original source... Go to PubMed...
    17. Yoshitomi, S.; Ikemoto, K.; Takahashi, J.; Miki, H.; Namba, M.; Asahi, S. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applicationson drug metabolism and toxicology. Toxicol In Vitro. 2001, 15, 245-256. Go to original source... Go to PubMed...
    18. Svobodova, H., Jost, P., Stetina, R. Comparison of potential cytotoxicity and genotoxicity of selected antidotes against organophosphates inhibiting acetylcholinesterase. Mil. Med. Sci. Lett. 2011, 80, 142-149.
    19. Galloway, S. M.; Aardema, M. J.; Ishidate, M.; Ivett, J. L.; Kirkland, D. J.; Morita, T.; Mosesso, P.; Sofuni, T. Report from working group on in vitro tests for chromosomal aberrations. Mutat Res. 1994, 312, 241-61. Go to original source... Go to PubMed...
    20. Hecht, S. S. Tobacco smoke carcinogens and breast cancer. Environm. Molec. Mutagen. 2002, 39, 119-126. Go to original source... Go to PubMed...
    21. Shimada, T.; Fujii-Kuriyama, Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. 2004, 95, 1-6. Go to original source... Go to PubMed...
    22. Shimada, T.; Oda, Y.; Gillam, E. M.; Guengerich, F. P.; Inoue K. Metabolic activatiom of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salemonella typhimurium NM2009. Drug Metab Dispos. 2001, 29, 1176-1182.

    Return to the content